Zacks SCR - Co-Host 

Zacks Small-Cap Research, a preferred provider in the OTC Markets Group’s Research Marketplace, prepares independent company-sponsored research and related content for distribution through a multitude of investor and media channels, both traditional and social, delivering broad awareness worldwide among serious, long-term investors.  We have a team of 6 life sciences-qualified analysts creating deep understanding of companies, hopefully generating significant interest in investment through the depth of their research and the breadth of our distribution.  Please visit our website https://scr.zacks.com to evaluate all.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) 

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biopharmaceutical company developing cancer treatments using its proprietary INTASYL® technology, a patented form of siRNA (short interfering RNA) gene silencing that works by switching off specific genes that allow tumors to evade the immune system. Rather than attacking cancer cells directly, INTASYL reactivates the body's own T cells, a type of immune cell, so they can more effectively identify and kill tumors. Phio's lead program, PH-762, targets the PD-1 gene in skin cancer and completed the treatment phase of a Phase 1b clinical trial in January 2026, with 22 patients treated across five escalating dose cohorts. A second program, PH-894, targets the BRD4 gene across a broader range of cancers and has completed the studies required to file for FDA authorization to begin clinical testing. Phio holds 59 issued patents with protection extending to 2044 and carries no debt.

Jupiter Neurosciences, Inc. (NASDAQ: JUNS)

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage pharmaceutical company built around JOTROL, a patented resveratrol formulation that has demonstrated materially higher bioavailability than earlier versions of the compound. Based in Jupiter, Florida, the company operates a dual-path business model: advancing a therapeutic pipeline targeting neuroinflammation and central nervous system disorders while commercializing Nugevia, a premium longevity supplement line using the same delivery technology. On the pharmaceutical side, the FDA cleared the company's IND application in November 2025, authorizing a Phase 2A clinical trial in Parkinson's disease. The company is also exploring potential applications in Alzheimer's disease, Friedreich's Ataxia, Mucopolysaccharidoses Type I, and MELAS. Jupiter's consumer business launched in 2025 with three Nugevia products (GLO, PWR, and MND), each targeting pillars of healthy aging. Jupiter completed its IPO in December 2024 and is led by Christer Rosén, Founder, Chairman, and CEO.

Bora Pharmaceuticals (OTCQX: BORAY | TWSE: 6472)

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.

Prostatype Genomics AB (OTCQB: PGABF | Nasdaq First North: PROGEN)

Prostate cancer is one of the most common forms of cancer and approximately 1.3 million men are diagnosed annually. Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test Prostatype®. Prostatype® is a genetic test that provides a comprehensive assessment of the aggressiveness of prostate cancer.

MetaVia Inc. (NASDAQ: MTVA)

MetaVia is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.

Avicanna Inc. (OTCQX: AVCNF | TSX: AVCN)

Avicanna is a Canadian commercial-stage biopharmaceutical company established in research, development, and commercialization of evidence-based cannabinoid products for the global consumer, as well as medical and pharmaceutical market segments. Avicanna conducts its own R&D and collaborates with leading Canadian academic and medical institutions in Canada. Avicanna has established an industry leading scientific platform that includes R&D and clinical development and has led to the commercialization of over thirty proprietary products and robust pharmaceutical pipeline.

Aethlon Medical (NASDAQ: AEMD) 

Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.

Dyadic International (NASDAQ: DYAI)

Dyadic is a global biotechnology company focused on the scalable production of high-value, precision-engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications.

Beyond Air, Inc. (Nasdaq: XAIR)

Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).

Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its lead program, CAD-1005, is a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. CAD-1005 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration, as well as orphan drug status from the European Medicines Agency. Second-generation 12-LOX oral therapeutics are also under development.

The Company’s broader pipeline includes tecarfarin, a Phase 3-ready oral vitamin K antagonist for the treatment of patients with end-stage kidney disease and those with left ventricular assist devices, and frunexian, a parenteral, clinical-stage Factor XIa inhibitor designed for use in acute hospital settings. For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.

Amplia Therapeutics Ltd. (OTCQB: INNMF | ASX: ATX)

Amplia Therapeutics Limited (ASX: ATX) is an Australian, clinical-stage, drug development company focused on the development of two potent, orally-available inhibitors of Focal Adhesion Kinase (FAK) for the treatment of cancer and fibrotic diseases.

The first of these drugs, narmafotinib (AMP945), is a highly selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). Orphan Drug Designations for pancreatic cancer and IPF have been granted by the US FDA. The FDA has also cleared Amplia’s investigational new drug (IND) submission to allow for a clinical trial in pancreatic cancer in the US.

Amplia’s second pipeline drug, AMP886, inhibits FAK and also inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is currently being evaluated in preclinical models of cancer.

Amplia’s pipeline drugs were originally developed by the Cancer Therapeutics CRC (CTx), an Australian industry/academic collaboration that included leading cancer and drug discovery researchers at Australia’s top cancer research institutes. Amplia was established to advance these promising drugs into clinical development and commercialisation.

Amplia’s Board and Management team includes highly experienced and well-credentialed life-science executives who have extensive international experience in drug development, pharmaceuticals, and life-sciences deal-making.

Jaguar Health, Inc. (Nasdaq: JAGX)

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, and bowel incontinence. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo Pharmaceuticals’ crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit napotherapeutics.com. For more information about Magdalena Biosciences, visit magdalenabiosciences.com.

SeaStar Medical Holding Corporation (Nasdaq: ICU)

SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. Our first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA-approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic-like condition in critically ill pediatric patients. Our Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. We are currently conducting a pivotal trial of our SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.